NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $8.90 -0.17 (-1.87%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Monte Rosa Therapeutics Stock (NASDAQ:GLUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GLUE alerts:Sign Up Key Stats Today's Range$8.75▼$9.2850-Day Range$9.07▼$14.3252-Week Range$8.75▼$25.77Volume613,261 shsAverage Volume1.36 million shsMarket Capitalization$759.99 millionP/E RatioN/ADividend YieldN/APrice Target$26.44Consensus RatingModerate Buy Company Overview Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway. Monte Rosa has also studied MRT-2359, a GSPT1 degrader for certain cancers. Founded in 2019, Monte Rosa is headquartered in Boston, Massachusetts, and has operations in Basel, Switzerland. The company is led by co-founder and Chief Executive Officer Markus Warmuth.AI Generated. May Contain Errors. Read More Monte Rosa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreGLUE MarketRank™: 1.921188982815 of 5 starsMonte Rosa Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 1319th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialMonte Rosa Therapeutics has a consensus price target of $26.44, representing about 197.3% upside from its current price of $8.89.Amount of Analyst CoverageMonte Rosa Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Monte Rosa Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to decrease in the coming year, from ($0.94) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.12% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 15.68, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently increased by 0.95%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.31 News SentimentMonte Rosa Therapeutics has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Monte Rosa Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137.00 in company stock.Percentage Held by Insiders6.40% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLUE Stock News HeadlinesMonte Rosa: A Risky Contrarian Buy As Market Abandons Bull ThesisNovember 17 at 12:09 PM | seekingalpha.comMonte Rosa Therapeutics: The Market Is Punishing NEK7 For IL-6's FailureNovember 17 at 9:03 AM | seekingalpha.comChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when trying to reach their money. The outage lasted hours. Cedar Gold Group points out that physical gold has no login, no server and needs no one's permission. Its free Wealth Protection Playbook shows how to keep part of your savings outside the banking system.November 19 at 1:00 AM | Cedar Gold Group (Ad)Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 16 at 6:27 PM | seekingalpha.comMonte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 16 at 10:12 AM | seekingalpha.comPiper Sandler Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)November 12, 2026 | theglobeandmail.comHC Wainwright Has Bullish Forecast for GLUE FY2026 EarningsNovember 12, 2026 | americanbankingnews.comMonte Rosa Therapeutics Presents Preclinical Data On MRT-8102 In GoutNovember 9, 2026 | marketscreener.comMSee More Headlines GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $15.68 at the beginning of the year. Since then, GLUE shares have decreased by 43.3% and is now trading at $8.8940. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) announced its quarterly earnings data on Thursday, November, 5th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.24. The business had revenue of $54.37 million for the quarter, compared to analysts' expectations of $33.87 million. Monte Rosa Therapeutics had a negative trailing twelve-month return on equity of 30.14% and a negative net margin of 186.24%. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Wednesday, June 23rd 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' top institutional shareholders include State Street Corp (4.36%), Goldman Sachs Group Inc. (1.02%), Nantahala Capital Management LLC (0.84%) and Empowered Funds LLC (0.45%). Insiders that own company stock include Versant Venture Capital Vi, L, Markus Warmuth, Sharon Townson, Jennifer Champoux, Filip Janku, Filip Janku, Philip Nickson, Matthew Bowen, Edmund Dunn, Chandra P Leo and Anthony M Manning. View institutional ownership trends. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monte Rosa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include NVIDIA (NVDA), Atai Beckley (ATAI), Broadcom (AVGO), CorMedix (CRMD), Definium Therapeutics (DFTX), Denali Therapeutics (DNLI) and GH Research (GHRS). Company Calendar Last Earnings11/05/2026Today11/19/202638th Annual Healthcare Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GLUE's financial health is in the Yellow zone, according to TradeSmith. GLUE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GLUE CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees173Year Founded2018Price Target and Rating Average Price Target for Monte Rosa Therapeutics$26.44 High Price Target$37.00 Low Price Target$19.00 Potential Upside/Downside+198.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.63 million Net Margins-186.24% Pretax Margin-184.77% Return on Equity-30.14% Return on Assets-20.35% Debt Debt-to-Equity RatioN/A Current Ratio10.32 Quick Ratio10.32 Sales & Book Value Annual Sales$70.33 million Price / Sales10.77 Cash FlowN/A Price / Cash FlowN/A Book Value$5.81 per share Price / Book1.53Miscellaneous Outstanding Shares85,450,000Free Float79,981,000Market Cap$757.51 million OptionableOptionable Beta1.40 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GLUE) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersDrama In The Trade Rooms! (Black Friday deal to blame?)Base Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Frida...Base Camp Trading | SponsoredChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDon’t delete this, read it todayPorter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has nev...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.